Connect with us


3 Penny Stocks to Watch Under $1 Right Now

Check these three under $1 penny stocks out for your watchlist
The post 3 Penny Stocks to Watch Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information |



Are These Under $1 Penny Stocks Worth Buying in January?

If you’re looking for cheap penny stocks to buy, there are hundreds of options to choose from. But, when we go under $1, investors should fully understand the level of volatility that they’re comfortable with. While all penny stocks or blue chips can be volatile, we tend to see a higher degree of fluctuations as the price of a stock gets cheaper. 

[Read More] Best Penny Stocks To Buy Now? 4 On Webull With Bullish User Ratings

So, always have a thorough understanding of what your tolerance for risk is and what your investing goals are. In 2022, there is also a lot for traders to keep track of. This means staying up to date with the latest news and events as it pertains to penny stocks. Right now, the largest impacting factor as we all know is Covid and the Omicron variant.

While it is hard to say with certainty what will happen with this variant in the long term, we do know that right now, it is causing large fluctuations across the board. In addition to this, we’re also witnessing movement as a result of economic factors in the U.S. 

This includes inflation, interest rates, employment, and more. But because of that, there are also a lot of opportunities to take advantage of right now. So, know exactly what you are looking for and always make sure to use your trading strategy. Considering this, let’s take a look at three penny stocks to watch under $1 right now.

3 Under $1 Penny Stocks to Watch in January 2022

  1. Jaguar Health Inc. (NASDAQ: JAGX
  2. Sos Ltd. (NYSE: SOS
  3. Zomedica Corp. (NYSE: ZOM

Jaguar Health Inc. (NASDAQ: JAGX) 

One of the bigger gainers of the day so far is JAGX stock, pushing up by around 7.5% at midday. While shares of JAGX stock are down by as much as 90% in the past twelve months, we have seen a small bullish turnaround recently. So, why exactly is JAGX stock moving up right now? Well, the company announced today during premarket that it will be hosting a treatment forum for veterinarians to discuss chemotherapy-induced diarrhea in dogs on January 16th. 

This coincides with the announcement of its Canalevia compound which received conditional FDA approval on December 21st of last year. If you’re not familiar, Jaguar Health is a veterinary health-focused biotech penny stock. The company is working on a variety of plant-based, non-opioid pharmaceuticals for both people and animals with GI distress. In addition, its subsidiary Napo Pharmaceuticals is working on the same goal. 

With more and more people adopting companion animals during the pandemic, Jaguar Health has seen vastly increased popularity as of late. So, while its stock performance is nothing to write home about, the company is working hard to continue growing. With all of this in mind, will it be on your list of penny stocks to watch?

Sos Ltd. (NYSE: SOS) 

Another penny stock that investors are watching right now is SOS stock. With a 4.9% gain at EOD, shares of SOS stock have increased by over 7.7% in the past five days. Now, there are a few reasons why SOS stock could be increasing right now, although the company has not announced any specific news. 

But, following the recent crypto crash which saw BTC dip below $40,000, most cryptocurrencies are pushing up once more. Because SOS has such a heavy hand in blockchain and Bitcoin, the company has a large amount of exposure to the industry as a whole. For some context, Sos operates as a blockchain-based tech penny stock. It offers big data, AI, satellite capabilities, 5G, and more. These products are used by financial institutions, medical industries, auto manufacturers, and much more. 

[Read More] 3 Top Penny Stocks to Add to Your Watchlist in Mid-January

Back in November, SOS announced a securities purchase agreement with an accredited investors to purchase $90.1 million of its American Depository Shares. In this registered direct offering, the company plans to move forward with its North American business as well as general corporate needs and working capital. Considering this, does SOS have a place on your penny stocks watchlist?


Zomedica Corp. (NYSE: ZOM) 

Another decent gainer of the day so far is ZOM stock which climbed by over 7% at EOD on January 12th. This brings its five-day gain to almost 10%, which is no small feat. The most recent news from Zomedica comes as the company announced a letter to its shareholders from the CEO. 

“Our general strategy is to offer innovative diagnostic and therapeutic products to Veterinarians that provide a benefit to both them and the patients they serve. As you know, Zomedica launched the TRUFORMA® product line this past May, signaling a shift in the primary focus of the Company from development to commercialization.” 

CEO of Zomedica, Larry Heaton

Now that the company is moving into the commercialization stage of this product, it should begin to work on building its revenue. And, this has been a major concern with investors as the company has not had the most striking balance sheet in the past few quarters. So, as a veterinary diagnostics company, Zomedica could have a lot to offer investors moving forward. With that considered, will it be on your list of penny stocks to watch under $1?


Are Cheap Penny Stocks Worth Buying?

When it comes to finding cheap penny stocks, investors need to do all the proper due diligence to make sure that the companies are worth it. This means looking at financial statements, upcoming announcements, and industry-wide events that are worth noting. Because there is so much going on in the stock market right now, these factors all can contribute greatly to your chance of making money with penny stocks. And because of the state of the U.S. economy, there is also a lot that is in flux right now. 

[Read More] Check These 3 Penny Stocks Out For Your Morning Watchlist

So, knowing what your trading strategy is and how to use that as an advantage, will both be crucial in making money with small caps in 2022. While it can be difficult considering the world we’re living in, there are plenty of opportunities to take advantage of. With that in mind, do you think that cheap penny stocks are worth buying in 2022?

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!

The post 3 Penny Stocks to Watch Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information |

Read More

Continue Reading


Pfizer Inc (NYSE: PFE) To Acquire Global Blood Therapeutics For $5 Billion

According to sources familiar with the matter, the Wall Street Journal reported that Pfizer Inc (NYSE: PFE) was in advanced discussions to acquire pharmaceutical…



According to sources familiar with the matter, the Wall Street Journal reported that Pfizer Inc (NYSE: PFE) was in advanced discussions to acquire pharmaceutical company Global Blood Therapeutics (NASDAQ: GBT) for $5 billion.

Pfizer, too, acquired Global Blood Therapeutics 

Pfizer wants to close a deal soon, but there are still other interested parties, according to the article.

Global Blood Therapeutics, which manufactures Oxbryta, the blood disorder medication, saw its shares jump 44%  on Friday afternoon to a two-year high. As of Thursday’s closing, the company’s market cap was $3.12 billion.

A spokesman for Global Blood stated the company does not “comment on market rumors or speculation,” while Pfizer declined to respond on the matter.

With plenty of cash left over after selling its COVID-19 vaccine, New York-based Pfizer is searching for deals that may generate billions of dollars annual sales by 2030.

Its $11.6 billion acquisition of migraine medication manufacturer Biohaven Pharmaceutical Holding (NASDAQ: BHVN) in May was the most recent in a series of purchases that also included Trillium Therapeutics and Arena Pharmaceuticals in recent years.

Oxbryta received approval last year for sickle cell disease management 

In 2019, the US government approved Global Blood’s Oxbryta to manage sickle cell disease in individuals aged 12 and over. The oral medication was approved in December 2021 to treat the illness in younger children. The drug’s sales increased by almost 50% to $194.7 million in 2021.

After a gloomy start to the calendar year, when a lack of significant purchases and clinical-stage treatment failures lowered investor morale and restricted funding, the biotech dealmaking pace has recently picked up again.

Also, Amgen Inc (NASDAQ: AMGN) also decided to purchase ChemoCentryx Inc on Thursday for $3.7 billion to obtain access to a possible breakthrough medication for inflammatory illnesses. AstraZeneca’s $39 billion acquisition of Alexion Pharmaceuticals in 2020 has put the realm of immune diseases in the limelight. The deal, which was announced before trading opened, will also give the corporation control of at least two investigational immune disorders medicines.

Please make sure to read and completely understand our disclaimer at While reading this article one must assume that we may be compensated for posting this content on our website.

The post Pfizer Inc (NYSE: PFE) To Acquire Global Blood Therapeutics For $5 Billion appeared first on Wall Street PR.

Read More

Continue Reading


AEMD: Positive Results in a Range of Conditions, Including COVID-19 & Monkey Pox

By M. Marin
Expanding the Potential Indications for Hemopurifier Treatment
Aethlon Medical’s (NASDAQ: AEMD)…



By M. Marin



Expanding the Potential Indications for Hemopurifier Treatment

Aethlon Medical's (NASDAQ: AEMD) clinical trials are moving forward and expanding, as AEMD continues to demonstrate the effectiveness of its lead product, the Aethlon Hemopurifier®, in a broad range of viruses and conditions in single patient emergency use cases and in in vitro analysis, including COVID-19 and various variants and Monkey Pox, among others. The Aethlon Hemopurifier® is being studied in a severe COVID-19 clinical trial under the company's open IDE (Investigational Device Exemption) for life-threatening viral infections.

The safety and feasibility of the Hemopurifier is being evaluated in an Early Feasibility Study (EFS) that will enroll up to 40 COVID-19 ICU patients. The first patient was enrolled in this study in June 2022 and has completed the Hemopurifier treatment. AEMD has nine fully activated hospitals that are actively screening patients for the trial.

In addition to this study, the Hemopurifier has demonstrated positive results in two severely ill patients under individual emergency use and in in vitro analysis. The Hemopurifier has produced positive results in binding seven variants of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) virus in vitro, as discussed in an article1  that AEMD's CEO Dr. Charles J. Fisher Jr. and the company's Chief Medical Officer Dr. Steven LaRosa contributed to.

The company is also conducting a study of the impact of the ...

Full story available on

Read More

Continue Reading


Where Are Interest Rates Headed? Is The Fed Correct Or The Eurodollar Curve?

Where Are Interest Rates Headed? Is The Fed Correct Or The Eurodollar Curve?

Authored by Mike Shedlock via,

The Eurodollar curve…



Where Are Interest Rates Headed? Is The Fed Correct Or The Eurodollar Curve?

Authored by Mike Shedlock via,

The Eurodollar curve implies four quarter-point cuts are on the way starting in 2023. The Fed believes otherwise. Let's discuss stock market implications.

Data from CME and Fed via Wall Street Journal.

Eurodollar Curve

The eurodollar curve has nothing to do with euros or dollars. Rather it is an interest rate curve and one of the world's most widely traded futures.

After peaking at about 3.9% this year, eurodollar betters believe the Fed will then cut rates all the way down to 2.8%. 

Five Not-Quite-Impossible Things the Market Believes

Wall Street Journal Contributor James Macintosh discussed the above chart in Five Not-Quite-Impossible Things the Market Believes

  1. Inflation is transitory. 

  2. The Fed realizes this in time.

  3. The jobs market cools enough to slow wage rises. 

  4. But not so much it means falling household spending.

  5. So consumer spending rises in real terms. 

In reference to the led chart, Macintosh says "The first assumption is the hardest to believe."

I disagree. The hardest thing to believe is the overall goldilocks scenario and that the current rally makes any sense at all. 

Inflation may easily come down if the Fed tightens too much too fast causing a severe recession. What would that do to corporate profits? 

But assume otherwise, that inflation does not come down more. What would that do to corporate profits? 

While any of the first three points may easily be correct, the combination of all five being correct and that stocks will rise in a goldilocks scenario is what I find hard to believe.

Is the Market Forward Looking?

Goldilocks proponents will tell you that the market is forward looking. 

The market isn't forward looking and never was. It is a coincident indicator of current sentiment, wildly wrong at major turns.

If the market was forward looking, what precisely was it looking forward to at the November 2007 peak with recession starting the next month? 

What was it looking forward to at the 1929 peak, the 1933 bottom, the 2009 bottom or any other top or bottom?

The Fed Will Hike Until It Breaks Something

I believe the eurodollar curve is more likely to be correct than the Fed. When has the Fed gotten much of anything correct?

The eurodollar view has two ways to win. The first is the Fed actually does tame inflation to the degree that it wants.

That's possible in a severe enough recession. And the global picture is easily weak enough for that to happen.

The second way the eurodollar curve might be correct is if the Fed breaks the credit market. 

The Fed would immediately reverse course, regardless of inflation, should that happen. 

Neither a credit event nor strong recession would be good for the stock market.

The least likely thing is that the Fed achieves a goldilocks soft landing. Yet, assume that happens. 

Macintosh says, and I agree, "The bull case that stocks and corporate bonds are pricing requires the combination of low joblessness and wage rises to allow spending to rise faster than inflation even after pandemic savings run out. But not so much faster that it hits capacity constraints and accelerates inflation."

The problem with goldilocks is stocks are priced so much beyond perfection that they may decline anyway. 

Globally Speaking 

  1. China Does Surprise Rate Cut to Help Its Economy, But It Won't Work

  2. German Costs to Ship by Barge are up Twenty Times and May Soon Be Impossible

  3. UK Average Electricity Cost Will Soar to $5,370 Per Year By 2023

  4. US Industries Are Buckling Under Pressure of Surging Electricity Costs

Good luck with goldilocks, especially with the Fed still hiking. 

*  *  *

Please Subscribe to MishTalk Email Alerts.

Tyler Durden Wed, 08/17/2022 - 09:45

Read More

Continue Reading